论文部分内容阅读
目的了解医生、药师和患者在开具处方、调配药品和使用生殖毒性药品3个环节时,对育龄人群的安全用药知晓情况,制定干预措施做好妊娠风险防范计划,确保育龄人群使用生殖毒性药品的安全性。方法对风湿免疫科和皮肤科医生关于生殖毒性药品安全使用及开具处方时的注意事项先后做两次调查问卷,对全部药师开展妊娠期生殖毒性药品知识培训并进行考核;对育龄人群安全使用生殖毒性药品的知晓情况先后两次做调查问卷并开展面对面用药教育。结果知道哪些药物是FDA妊娠分级为X级药物的医生人数比例,由干预前的29%升高到干预后的85%;告知患者生殖毒性药物有潜在的风险的药师人数比例,由干预前的65%升高到干预后的100%;了解生殖毒性药品有风险的患者人数比例,由干预前的35%升高到干预后的100%。结论开展生殖毒性课题干预研究具有可行性和有效性,具有重要意义。
Objective To understand the safety of physicians, pharmacists and patients in child-bearing age when they prescribe, formulate drugs and use reproductive toxic drugs, make interventions to prevent pregnancy risks and ensure reproductive toxic drugs safety. Methods Rheumatology and dermatologists used the survey questionnaire on the safe use of reproductive toxic drugs and prescribing prescriptions to conduct the training and assessment on the knowledge of reproductive toxic drugs during pregnancy for all pharmacists. The awareness of toxic drugs have done the questionnaire twice and conduct face-to-face drug education. As a result, the percentage of physicians who reported that the drug was classified as Class X at pregnancy was increased from 29% pre-intervention to 85% post-intervention; and the proportion of pharmacists reporting potential risks to reproductive toxicants from pre-intervention 65% increase to 100% after intervention; the proportion of patients at risk of developing genotoxic drugs increased from 35% before intervention to 100% after intervention. Conclusion It is feasible and effective to carry out the intervention research on reproductive toxicity.